AI Meets Pharma: A 2025 Roundup of Transformative Collaborations Reshaping Drug Discovery

　　【Pharmaceutical Network Industry Dynamics】In the era of rapid technological advancement, the integration of artificial intelligence (AI) with the pharmaceutical industry is rapidly reshaping the landscape of new drug development. Since 2025, this field has continuously seen remarkable collaborative projects, bringing new hope for solving medical challenges and improving human health. Recently, Crystal Pharmatech announced a significant AI-driven pharmaceutical collaboration with DoveTree, becoming the focal point of the industry.
 

Crystal Tech Holdings announced on the evening of August 5 that its subsidiary, Crystal Tech, had completed a pipeline cooperation agreement with biopharmaceutical company DoveTree, with a total order value of approximately HKD 47 billion (approximately USD 5.99 billion). Crystal Tech has received an initial payment of approximately USD 51 million, with the potential to receive an additional USD 49 million in further payments, as well as up to approximately USD 5.89 billion in potential milestone payments and sales royalties. According to the agreement, Crystal Tech will utilize its "AI+Robot"End-to-end artificial intelligence drug discovery platform" will develop small molecule and antibody candidate drugs for targets selected by DoveTree in the fields of oncology, immunology and inflammatory diseases, neurological disorders, and metabolic disorders. DoveTree holds the global exclusive rights for the development and commercialization of these related drugs. This collaboration not only sets a new record for order scale in the field of "artificial intelligence (AI) + robotics" drug research and development but also highlights the critical role of AI technology in addressing complex targets and accelerating the drug discovery process.
 

In addition to the notable collaboration between Crystal Pharmatech and DoveTree, there have been several other remarkable partnerships in the AI + pharmaceuticals field since 2025. Walvax Biotechnology Co., Ltd. has established a strategic partnership with Zelixir, an innovative pioneer in AI-driven synthetic biology. The aim of this collaboration is to apply Zelixir's bio-computing technology, which combines AI modeling with physics-based simulations, to Walvax’s human vaccine research and development efforts. Key areas of focus include using AI technology to accelerate protein (including enzyme) discovery and design processes, providing authorized services for AI bio-computing platforms, building intelligent R&D infrastructure, and offering deeply customized AI bio-computing solutions tailored to specific vaccine product needs. Through this collaboration, it is expected to expedite technological innovation and the intelligent transformation of the vaccine industry, contributing to global public health.
 

CSPC and AstraZeneca have also reached a strategic R&D collaboration agreement. CSPC will utilize its AI engine dual-driven efficient drug discovery platform to discover and develop novel oral small-molecule candidate drugs for AstraZeneca. The platform uses AI technology to analyze the binding modes of target proteins with existing compound molecules and conducts targeted optimization to screen out highly effective small molecules with excellent development potential. According to the agreement, CSPC will discover preclinical candidate drugs with multi-indication disease treatment potential for several targets selected by AstraZeneca. AstraZeneca has the right to exercise an option to obtain exclusive global rights for development, manufacturing, and commercialization. CSPC will receive an upfront payment of $110 million and is eligible to receive up to $1.62 billion in potential R&D milestone payments, up to $3.6 billion in potential sales milestone payments, as well as tiered single-digit royalties based on annual net product sales.
 

In terms of deepening cooperation, XtalPi and Pfizer have expanded their strategic partnership to jointly develop a next-generation molecular simulation platform to drive new drug discovery. This collaboration aims to further integrate the precision of advanced physical algorithms with the speed and scalability of cutting-edge AI models, thereby comprehensively enhancing the efficiency, accuracy, and breadth of chemical space coverage of the molecular simulation platform, significantly accelerating the discovery and development process of small molecule drugs. Building on the existing collaborative R&D achievements from their prior strategic partnership, the current platform will be reinforced and upgraded to create predictive tools that combine high accuracy with higher throughput advantages, addressing Pfizer's rapidly expanding small molecule chemical space and continuously evolving R&D needs. After the upgrade, the teams from both sides will develop more accurate predictive models tailored to Pfizer’s proprietary chemical space and expand the platform’s application scenarios in the field of small molecule drug discovery. XtalPi will also deploy its self-developed Free Energy Perturbation (FEP) cloud computing platform locally for Pfizer, covering the entire process from parameter customization to FEP calculations, fully empowering Pfizer's drug discovery efforts.
 

In February 2025, XtalPi signed a strategic cooperation agreement worth tens of millions of RMB with JW Pharmaceutical, a South Korean pharmaceutical company. XtalPi will provide JW with a set of automated drug discovery workstations and an AI-based chemical reaction optimization platform to comprehensively enhance the efficiency, reproducibility, and success rate of JW's drug research and development. XtalPi will deploy a series of high-throughput automated synthesis workstations, AI reaction condition optimization systems, and intelligent analysis platforms for JW. Through Bayesian optimization, digital management, and automated laboratory technologies, it is expected to effectively improve the success rate and reproducibility of chemical synthesis, shorten the drug development cycle, reduce R&D costs, and enhance the efficiency of new drug discovery.
 

In addition, Hanyu Pharmaceutical and Huawei Cloud Computing Technology Co., Ltd. held a comprehensive cooperation agreement signing ceremony on April 27. The two parties will cooperate in areas such as drug research and development, AI large model applications, digital platform construction, data governance, and AI talent empowerment. In terms of drug research and development, they will jointly develop large models for peptide and oligonucleotide drug research and development. Hanyu Pharmaceutical will rely on Huawei Cloud's Pangu drug molecule large model and various advanced large models' capabilities in data processing and deep learning, combined with its own profound accumulation in the field of drug research and development, aiming at molecular design and screening.Active Pharmaceutical IngredientsBreakthroughs in core areas such as process development, analytical method optimization, and clinical trial design have accelerated the new drug research and development process, improving efficiency and success rates. In terms of applying large AI models, Hanyu Pharmaceutical's key business scenarios—sales, production, finance, administration, and human resources—are being intelligently upgraded to build an intelligent operational system, supporting the company’s comprehensive digital transformation. This collaboration represents not only an active exploration of artificial intelligence technology applications in the pharmaceutical industry but also a pragmatic action in implementing the "Healthy China" and "Digital China" strategies.
 

These cooperation cases indicate that the AI + pharmaceuticals field is showing a booming development trend in 2025. With its powerful data processing and analysis capabilities, AI technology can play a key role in every aspect of drug research and development, from target discovery and drug molecule design to clinical trial optimization, injecting new vitality into the traditional pharmaceutical industry. The cooperation between pharmaceutical companies and AI technology companies continues to deepen, with increasingly diversified cooperation models, covering various forms such as joint R&D, technology licensing, and co-building platforms. These cooperations are expected not only to accelerate the new drug R&D process, reduce R&D costs, and improve R&D success rates, but more importantly, bring more innovative and effective therapeutic drugs to patients worldwide, driving the entire pharmaceutical industry into a new stage of development.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.